|
Acute coronary syndromes
Citations 1-10 of 914 total displayed.
|
Most recent content
(30 Jun 2009):
|
- Correspondence
Letter by Rosenstein and Parra Regarding Article, "Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel: Thrombolysis in Myocardial Infarction 38"
- Robert S. Rosenstein and David Parra
Circulation 2009; 119: e601, doi:10.1161/CIRCULATIONAHA.108.829838
[Full text]
- Correspondence
Response to Letter Regarding Article, "Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel: Thrombolysis in Myocardial Infarction 38"
- Stephen D. Wiviott, Eugene Braunwald, Sabina A. Murphy, Carolyn H. McCabe, Elliott M. Antman, Dominick J. Angiolillo, Simha Meisel, Anthony J. Dalby, Freek W.A. Verheugt, Shaun G. Goodman, Ramon Corbalan, and Drew A. Purdy
Circulation 2009; 119: e602-603e, doi:10.1161/CIRCULATIONAHA.108.844050
[Full text]
- Coronary Heart Disease
Soluble CXCL16 Predicts Long-Term Mortality in Acute Coronary Syndromes
- Anna M. Jansson, Pål Aukrust, Thor Ueland, Camilla Smith, Torbjørn Omland, Marianne Hartford, and Kenneth Caidahl
Circulation 119: 3181 -3188; published online before print as doi:10.1161/CIRCULATIONAHA.108.806877
[Abstract]
[Full text]
- Articles
Is It Time to Treat Depression in Patients With Cardiovascular Disease?
- William Whang and Karina W. Davidson
Circulation published June 29, 2009, doi:10.1161/CIRCULATIONAHA.109.881987
[Abstract]
|
Past content
(since Jan 1999):
|
- Interventional Cardiology
Comparison of Primary Percutaneous Coronary Intervention and Fibrinolytic Therapy in ST-Segment-Elevation Myocardial Infarction: Bayesian Hierarchical Meta-Analyses of Randomized Controlled Trials and Observational Studies
- Thao Huynh, Stephane Perron, Jennifer O'Loughlin, Lawrence Joseph, Michel Labrecque, Jack V. Tu, and Pierre Théroux
Circulation 119: 3101 -3109; published online before print as doi:10.1161/CIRCULATIONAHA.108.793745
[Abstract]
[Full text]
- Articles
Soluble CXCL16 Predicts Long-Term Mortality in Acute Coronary Syndromes
- Anna M. Jansson, Pål Aukrust, Thor Ueland, Camilla Smith, Torbjørn Omland, Marianne Hartford, and Kenneth Caidahl
Circulation published June 15, 2009, doi:10.1161/CIRCULATIONAHA.108.806877
[Abstract]
- Coronary Heart Disease
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
- APPRAISE Steering Committee and Investigators
Circulation 119: 2877 -2885; published online before print as doi:10.1161/CIRCULATIONAHA.108.832139
[Abstract]
[Full text]
- Articles
Comparison of Primary Percutaneous Coronary Intervention and Fibrinolytic Therapy in ST-Segment–Elevation Myocardial Infarction. Bayesian Hierarchical Meta-Analyses of Randomized Controlled Trials and Observational Studies
- Thao Huynh, Stephane Perron, Jennifer O'Loughlin, Lawrence Joseph, Michel Labrecque, Jack V. Tu, and Pierre Théroux
Circulation published June 8, 2009, doi:10.1161/CIRCULATIONAHA.108.793745
[Abstract]
- Clinician Update
Can We Override Clopidogrel Resistance?
- Ana Pena, Jean-Philippe Collet, Jean-Sébastien Hulot, Johanne Silvain, Olivier Barthélémy, Farzin Beygui, Christian Funck-Brentano, and Gilles Montalescot
Circulation 2009; 119: 2854-2857, doi:10.1161/CIRCULATIONAHA.108.857722
[Full text]
- Articles
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome. Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
- APPRAISE Steering Committee and Investigators
Circulation published May 26, 2009, doi:10.1161/CIRCULATIONAHA.108.832139
[Abstract]
|
|
